These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 33311713)

  • 1. Responsive and activable nanomedicines for remodeling the tumor microenvironment.
    Zhang Y; Han X; Nie G
    Nat Protoc; 2021 Jan; 16(1):405-430. PubMed ID: 33311713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hierarchically Releasing Bio-Responsive Nanoparticles for Complete Tumor Microenvironment Modulation via TGF-β Pathway Inhibition and TAF Reduction.
    Zhang J; Zuo T; Yang J; Hu Z; Wang Z; Xu R; Ma S; Wei Y; Shen Q
    ACS Appl Mater Interfaces; 2021 Jan; 13(2):2256-2268. PubMed ID: 33423468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing tumor penetration and targeting using size-minimized and zwitterionic nanomedicines.
    Zhang Y; Chen W; Yang C; Fan Q; Wu W; Jiang X
    J Control Release; 2016 Sep; 237():115-24. PubMed ID: 27397491
    [No Abstract]   [Full Text] [Related]  

  • 4. Nanotherapy Targeting the Tumor Microenvironment.
    Gong BS; Wang R; Xu HX; Miao MY; Yao ZZ
    Curr Cancer Drug Targets; 2019; 19(7):525-533. PubMed ID: 30569855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Near-infrared light and tumor microenvironment dual responsive size-switchable nanocapsules for multimodal tumor theranostics.
    Wang Z; Ju Y; Ali Z; Yin H; Sheng F; Lin J; Wang B; Hou Y
    Nat Commun; 2019 Sep; 10(1):4418. PubMed ID: 31562357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer nanomedicines harnessing tumor microenvironmental components.
    Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
    Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy.
    Muntimadugu E; Kommineni N; Khan W
    Pharmacol Res; 2017 Dec; 126():109-122. PubMed ID: 28511988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
    Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
    AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
    Li Z; Zhang L; Tang C; Yin C
    Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted, triggered drug delivery to tumor and biofilm microenvironments.
    Benoit DS; Koo H
    Nanomedicine (Lond); 2016 Apr; 11(8):873-9. PubMed ID: 26987892
    [No Abstract]   [Full Text] [Related]  

  • 12. Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics.
    Chen Q; Liu G; Liu S; Su H; Wang Y; Li J; Luo C
    Trends Pharmacol Sci; 2018 Jan; 39(1):59-74. PubMed ID: 29153879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting antitumor efficacy of nanoparticles by modulating tumor mechanical microenvironment.
    Zhang X; Zhang X; Yong T; Gan L; Yang X
    EBioMedicine; 2024 Jul; 105():105200. PubMed ID: 38876044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
    Mao C; Li F; Zhao Y; Debinski W; Ming X
    Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy.
    Yang S; Gao H
    Pharmacol Res; 2017 Dec; 126():97-108. PubMed ID: 28501517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
    Song Y; Tang C; Yin C
    Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
    Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
    Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precise Subcellular Organelle Targeting for Boosting Endogenous-Stimuli-Mediated Tumor Therapy.
    Zhen W; An S; Wang S; Hu W; Li Y; Jiang X; Li J
    Adv Mater; 2021 Dec; 33(51):e2101572. PubMed ID: 34611949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticles designed to regulate tumor microenvironment for cancer therapy.
    Li M; Zhang F; Su Y; Zhou J; Wang W
    Life Sci; 2018 May; 201():37-44. PubMed ID: 29577880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
    Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
    J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.